Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siRNA-ATM is a small interfering RNA (siRNA) designed to silence the expression of the ataxia-telangiectasia mutated (ATM) gene. ATM is a serine/threonine protein kinase that acts as a master regulator of the DNA damage response (DDR), particularly in response to DNA double-strand breaks caused by ionizing radiation. By utilizing the RNA interference (RNAi) pathway to degrade ATM mRNA, siRNA-ATM reduces ATM protein levels, thereby impairing the cell's ability to repair DNA damage. This mechanism is primarily explored as a strategy to overcome radioresistance in cancers such as glioblastoma, where glioma stem cells (GSCs) often exhibit high ATM expression. Preclinical research indicates that silencing ATM increases radiation-induced apoptosis and G2 phase arrest, effectively sensitizing tumor cells to radiotherapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on siRNA-ATM.